Paclitaxel topical - US Biotest

Drug Profile

Paclitaxel topical - US Biotest

Alternative Names: SOR 007

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator DFB Soria
  • Developer DFB Soria; US Biotest Inc
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Plaque psoriasis

Most Recent Events

  • 10 May 2017 DFB Soria plans a phase II trial for Cervical intraepithelial neoplasia (NCT03143491)
  • 10 Apr 2017 DFB Soria plans a phase II trial for Skin cancer (NCT03101358)
  • 22 Mar 2017 DFB Soria plans a phase II trial for Actinic keratosis (NCT03083470)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top